HLA-A2-restricted peptide epitopes of CD105 (endoglin) for cancer vaccination
The following invention is a new, peptide based vaccination against genetical stable tumor stroma-associated antigens. Because of significant upregulation of certain proteins (e.g. FAPα, CD105) tumor stroma cells are suitable targets for anti-tumor therapy. This technology employs these specific antigens in the vaccine design to avoid an immunologic attack on normal unaltered cells.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Properties of new materials for microchips
… can now be measured well. Reseachers of Delft University of Technology demonstrated measuring performance properties of ultrathin silicon membranes. Making ever smaller and more powerful chips requires new ultrathin…
Floating solar’s potential
… to support sustainable development by addressing climate, water, and energy goals holistically. A new study published this week in Nature Energy raises the potential for floating solar photovoltaics (FPV)…
Skyrmions move at record speeds
… a step towards the computing of the future. An international research team led by scientists from the CNRS1 has discovered that the magnetic nanobubbles2 known as skyrmions can be…